| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2021 | PCRX Pacira Biosciences, Inc. | Hastings Paul J75 | Director | Sell | 3,000 | $65.88 | $197,640.00 | -32.9% | - | - | |
| Mar 5, 2021 | LNTH Lantheus Holdings, Inc. | Heino Mary Anne50 | President &CEO | Sell | 27,157 | $18.26 | $495,837.94 | -3.7% | - | - | |
| Mar 5, 2021 | TEVA Teva Pharmaceutical Industries Ltd | O'Grady Brendan P. | EVP, North America Commercial | Sell | 19,608 | $10.56 | $207,090.64 | -25.9% | - | - | |
| Mar 5, 2021 | PBH Prestige Consumer Healthcare Inc. | Fritz Mary Beth57 | Senior VP Quality &Regulatory | Sell | 12,264 | $42.68 | $523,468.10 | -42.6% | - | - | |
| Mar 5, 2021 | IRWD Ironwood Pharmaceuticals Inc | Denner Alexander J66 | Director, 10% Owner | Buy | 775,000 | $10.01 | $7,758,750.00 | +1.6% | - | - | |
| Mar 4, 2021 | LNTH Lantheus Holdings, Inc. | Blanchfield Paul54 | Chief Commercial Officer | Sell | 4,061 | $18.40 | $74,722.40 | -13.3% | - | - | |
| Mar 4, 2021 | LNTH Lantheus Holdings, Inc. | Bolla John J. | Chief Operations Officer | Sell | 1,887 | $18.40 | $34,720.80 | -3.2% | - | - | |
| Mar 4, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Stark David Matthew53 | Exec. VP Chief Legal Officer | Sell | 13,930 | $10.57 | $147,185.77 | -82.4% | - | - | |
| Mar 4, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Fridriksdottir Hafrun47 | Executive VP, Global R&D | Sell | 9,515 | $10.57 | $100,536.44 | -11.5% | - | - | |
| Mar 4, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Drape Eric51 | Executive VP Global Operations | Sell | 6,183 | $10.58 | $65,443.35 | -10.1% | - | - | |
| Mar 4, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Dethlefs Sven | EVP Global Marketing&Portfolio | Sell | 6,012 | $10.57 | $63,523.39 | -7.2% | - | - | |
| Mar 4, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Daniell Richard | Exec. VP, European Commercial | Sell | 7,513 | $10.58 | $79,520.60 | -27.0% | - | - | |
| Mar 4, 2021 | LNTH Lantheus Holdings, Inc. | Marshall Robert J. Jr.53 | CFO And Treasurer | Sell | 2,280 | $18.40 | $41,952.00 | -2.9% | - | - | |
| Mar 4, 2021 | LNTH Lantheus Holdings, Inc. | Molnar Istvan | Chief Medical Officer | Sell | 4,027 | $18.40 | $74,096.80 | -13.8% | - | - | |
| Mar 4, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Nazzi Gianfranco | EVP, International Markets | Sell | 12,935 | $10.58 | $136,909.21 | -100% | - | - | |
| Mar 4, 2021 | EBS Emergent Biosolutions Inc. | Bailey Sue | Director | Sell | 8,168 | $92.37 | $754,478.16 | -25.1% | - | - | |
| Mar 3, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Dethlefs Sven | EVP Global Marketing&Portfolio | Sell | 606 | $10.86 | $6,582.74 | -0.9% | - | - | |
| Mar 3, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Nazzi Gianfranco | EVP, International Markets | Sell | 1,400 | $10.88 | $15,231.44 | -100% | - | - | |
| Mar 3, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Daniell Richard | Exec. VP, European Commercial | Sell | 993 | $10.88 | $10,803.44 | -7.7% | - | - | |
| Mar 3, 2021 | CRON Cronos Group Inc. | Gorenstein Michael Ryan77 | Executive Chairman | Sell | 344,015 | $10.83 | $3,724,796.40 | -2.0% | - | - | |
| Mar 3, 2021 | VTRS Viatris Inc | Cornwell W Don | Director | Buy | 3,000 | $13.84 | $41,514.90 | New | - | - | |
| Mar 3, 2021 | TEVA Teva Pharmaceutical Industries Ltd | O'Grady Brendan P. | EVP, North America Commercial | Sell | 15,548 | $10.85 | $168,630.73 | -33.8% | - | - | |
| Mar 2, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Fridriksdottir Hafrun47 | Executive VP, Global R&D | Sell | 50,000 | $10.82 | $540,890.00 | -43.8% | - | - | |
| Mar 2, 2021 | YCBD Cbdmd, Inc. | Raines William F III | Director | Sell | 20,000 | $4.04 | $80,748.00 | -93.7% | -26.0% | -79.0% | |
| Mar 2, 2021 | IRWD Ironwood Pharmaceuticals Inc | Denner Alexander J66 | Director | Buy | 1,350,000 | $9.44 | $12,737,960.00 | +3.1% | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.